Loading
A phase 3 trial of Loncastuximab tesirine, Rituximab, Gemcitabine in diffuse large b-cell lymphoma, run by ADC Therapeutics S.A., active and no longer recruiting.
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma is a phase 3 interventional study registered as NCT04384484 by ADC Therapeutics S.A., with 440 participants enrolled, started 2020-09-16 and due to reach its primary completion in 2026-03-31. Interventions recorded: Loncastuximab Tesirine, Rituximab, Gemcitabine, Oxaliplatin. Conditions listed: Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Loncastuximab tesirine, Antibody-drug conjugate (ADC), Diffuse large B-cell lymphoma.
Shares Loncastuximab tesirine, Antibody-drug conjugate (ADC), Diffuse large B-cell lymphoma.
Shares CAPOX (capecitabine, oxaliplatin), Rituximab, Gemcitabine, Monoclonal antibodies.
Shares Rituximab, Gemcitabine, Diffuse large B-cell lymphoma.
Shares CAPOX (capecitabine, oxaliplatin), Rituximab, Gemcitabine, Diffuse large B-cell lymphoma.
Shares CAPOX (capecitabine, oxaliplatin), Gemcitabine, Diffuse large B-cell lymphoma.
Shares Rituximab, Monoclonal antibodies, Antibody-drug conjugate (ADC), Diffuse large B-cell lymphoma.
Shares Rituximab, Monoclonal antibodies, Diffuse large B-cell lymphoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/